mHealth Apps Market (By Type: Nutrition & Diet, Women's Health, Medication Adherence, Fitness, Lifestyle Management, Healthcare, Providers/Payers, Disease Management, and Others) - Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2022 - 2030

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global mHealth Apps Market, By Type

7.1. mHealth Apps Market, by Type, 2020-2030
7.1.1. Nutrition & Diet
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Women's Health
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Medication Adherence
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Fitness
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Lifestyle Management
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Healthcare Providers/Payers
7.1.6.1. Market Revenue and Forecast (2017-2030)
7.1.7. Disease Management
7.1.7.1. Market Revenue and Forecast (2017-2030)
7.1.8. Others
7.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global mHealth Apps Market, Regional Estimates and Trend Forecast

8.1. North America
8.1.1. Market Revenue and Forecast, by Type (2017-2030)
8.1.2. U.S.
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.2. Europe
8.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.2.2. UK
8.2.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.2.3. France
8.2.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.2.4. Rest of Europe
8.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
8.3. APAC
8.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.3.2. India
8.3.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.3.3. China
8.3.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
8.4. MEA
8.4.1. Market Revenue and Forecast, by Type (2017-2030)
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast, by Type (2017-2030)
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
8.5. Latin America
8.5.1. Market Revenue and Forecast, by Type (2017-2030)
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast, by Type (2017-2030)
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast, by Type (2017-2030)

Chapter 9. Company Profiles

9.1. Abbott Laboratories
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Johnson and Johnson
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. AstraZeneca PLC
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. Hoffmann-La Roche Ltd.
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. Novartis AG
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Bristol-Myers Squibb Company
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. GlaxoSmithKline plc
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. Merck and Co., Inc.
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
9.9. Pfizer, Inc.
9.9.1. Company Overview
9.9.2. Product Offerings
9.9.3. Financial Performance
9.9.4. Recent Initiatives
9.10. iHealth Labs Inc.
9.10.1. Company Overview
9.10.2. Product Offerings
9.10.3. Financial Performance
9.10.4. Recent Initiatives
9.11. Vivify Health
9.11.1. Company Overview
9.11.2. Product Offerings
9.11.3. Financial Performance
9.11.4. Recent Initiatives
9.12. Medtronic MiniMed, Inc.
9.12.1. Company Overview
9.12.2. Product Offerings
9.12.3. Financial Performance
9.12.4. Recent Initiatives

Chapter 10. Research Methodology

10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions

Chapter 11. Appendix

11.1. About Us
11.2. Glossary of Terms

PROCEED TO BUY

   USD 4500.00
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample